

Table SI. Ongoing clinical trials of ICI combination therapy in NSCLC.

| Clinical trial       | Setting   | Intervention   | Status                 |
|----------------------|---|--|------------------------|
| NCT02194738          | Lung adenocarcinoma, lung large cell carcinoma, resectable lung non-small cell carcinoma, Stage IB-IIIa NSCLC, Stage IB-IIIa lung squamous cell carcinoma | Pembrolizumab + carboplatin/cisplatin/gemcitabine hydrochloride/paclitaxel                     | Active, not recruiting |
| NCT02314481          | NSCLC without an actionable mutation  | Atezolizumab + cisplatin/carboplatin and pemetrexed, atezolizumab + carboplatin and paclitaxel | Active, not recruiting |
| NCT03944772          | EGFR-mutated NSCLC  | Durvalumab + carboplatin and pemetrexed  | Active, not recruiting |
| NCT04379635          | NSCLC   | Tislelizumab + cisplatin, paclitaxel, pemetrexed and carboplatin                               | Active, not recruiting |
| NCT02143466 (TATTON) | EGFR mutation positive advanced lung cancer   | Osimertinib plus durvalumab  | Active, not recruiting |
| NCT04449874          | NSCLC   | Atezolizumab + GDC-6036  | Recruiting             |
| NCT03178552          | Advanced or metastatic NSCLC  | Atezolizumab + vemurafenib (Cohort E)  | Active, not recruiting |
| NCT04591431          | NSCLC   | Erlotinib/alectinib/brigatinib/palbociclib/itacitinib + atezolizumab/nivolumab/ipilimumab      | Active, not recruiting |
| NCT04475939          | Metastatic and/or locally advanced NSCLC  | Niraparib + pembrolizumab  | Active, not recruiting |
| NCT02432963          | Solid tumors that have failed prior therapy   | p53MVA (modified vaccinia virus Ankara vaccine expressing p53) + pembrolizumab                 | Active, not recruiting |
| NCT02824965          | NSCLC   | CVA21 (oncolytic Coxsackie virus) + pembrolizumab  | Unknown status         |
| NCT03647163          | NSCLC and neuroendocrine carcinoma  | VSV-IFN $\beta$ -NIS/VSV-IFN $\beta$ -NIS + pembrolizumab                                      | Recruiting             |

NCT, National Clinical Trial; VSV-IFN $\beta$ -NIS, vesicular stomatitis virus expressing both interferon  $\beta$  and sodium iodide symporter genes; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.